Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	3.67T
Revenue (ttm)	1.48T
Net Income (ttm)	108.92B
Shares Out	12.68M
EPS (ttm)	8,589.65
PE Ratio	33.70
Forward PE	22.89
Dividend	1,250.00 (0.43%)
Ex-Dividend Date	Jun 27, 2025

Volume	48,212
Average Volume	100,732
Open	292,500
Previous Close	290,500
Day's Range	288,000 - 297,000
52-Week Range	214,500 - 375,000
Beta	0.69
RSI	47.89
Earnings Date	Jul 29, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,330
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.